The immune checkpoint inhibitor clinical landscape is bustling with activity, with more than 1,000 trials for currently available products scheduled to complete between 2018 and 2020.
Despite the challenges associated with the class – such as recent high-profile combination failures – opportunities remain.
However, the rapid ongoing development of agents means the available ‘white space’ is closing, or at least changing, almost on a weekly basis.
Dr. Andrew Merron, Executive Director, DRG Oncology reviews competitor activities and how drug developers can take advantage of the best opportunities for success:
Please complete the form for answers to the above questions: